Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 6:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 15,841 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: INFECTIONS Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Revaccination With Subunit Influenza A/Vietnam/1203/2004 (H5N1) Vaccine

NCT00240903
View directory record Official record
Conditions
Influenza
Interventions
Influenza A/Vietnam/1203/2004 (H5N1; sanofi pasteur)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 12, 2011 · Synced Oct 31, 2026, 6:40 AM EDT
Not listed Phase 2 Interventional

Two-drug Antibiotic Prophylaxis in Scheduled Cesarean Deliveries

NCT03960970
View directory record Official record
Conditions
Endometritis, Cesarean Section; Infection, Wound Infection
Interventions
Azithromycin 500 mg, Mefoxin 2g
Drug
Lead sponsor
RWJ Barnabas Health at Jersey City Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Jersey City, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 31, 2026, 6:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected Adults

NCT03699241
View directory record Official record
Conditions
HIV Infections
Interventions
BG505 SOSIP.664 gp140, adjuvanted, Placebo
Biological
Lead sponsor
International AIDS Vaccine Initiative
Network
Eligibility
18 Years to 50 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
2
States / cities
Boston, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Oct 31, 2026, 6:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Seminal Fluid on the Colon Wall; Implications for HIV Transmission

NCT01053741
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV)
Interventions
Radiolabeled autologous seminal fluid, Radiolabeled Normosol-R
Biological
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 25, 2017 · Synced Oct 31, 2026, 6:40 AM EDT
Terminated Phase 1 Interventional Results available

Telavancin Pediatric PK Study (Ages >12 Months to 17 Years)

NCT02013141
View directory record Official record
Conditions
Gram-Positive Bacterial Infections
Interventions
Telavancin
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
12 Months to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
7
States / cities
Little Rock, Arkansas • Orange, California • San Diego, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced Oct 31, 2026, 6:40 AM EDT
Terminated Phase 2 Interventional

Heparin Anticoagulation in Septic Shock

NCT03378466
View directory record Official record
Conditions
Septic Shock, Vasodilatory Shock
Interventions
Unfractionated heparin, Venous thromboprophylaxis (VTE)
Drug · Other
Lead sponsor
University of Manitoba
Other
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Oct 31, 2026, 6:40 AM EDT
Completed Phase 1 Interventional Results available

Drug Interaction Study With BI 201335 and Methadone or Buprenorphine/Naloxone

NCT01637922
View directory record Official record
Conditions
Hepatitis C
Interventions
BI 201335
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 64 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
3
States / cities
Atlanta, Georgia • Overland Park, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 3, 2015 · Synced Oct 31, 2026, 6:40 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Multicenter Trial of Antibiotic Eluting Graft for Promoting New Bone Growth in/Near Infected Bone Cavities

NCT05361941
View directory record Official record
Conditions
Periprosthetic Joint Infections
Interventions
EP Granules with Tobramycin, empty voids
Device
Lead sponsor
Elute, Inc.
Industry
Eligibility
22 Years and older
Enrollment
204 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
16
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Skokie, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 31, 2026, 6:40 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)

NCT06891066
View directory record Official record
Conditions
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Interventions
ISL, ULO, BIC/FTC/TAF
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
11
States / cities
San Francisco, California • West Hollywood, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 31, 2026, 6:40 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients

NCT00055237
View directory record Official record
Conditions
Kaposi's Sarcoma, HIV Infections, HIV Seronegativity
Interventions
Bevacizumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 6, 2017 · Synced Oct 31, 2026, 6:40 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Observational Study of Blood Treated With Cytolin

NCT01048372
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
CytoDyn, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 21, 2013 · Synced Oct 31, 2026, 6:40 AM EDT
Completed No phase listed Observational

Effect of the COVID-19 Public Health Crisis on the Mental Health and Physical Well-Being of Cancer Patients, the Coping With COVID Study

NCT04652505
View directory record Official record
Conditions
COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2022 · Synced Oct 31, 2026, 6:40 AM EDT
Completed Phase 2 Interventional

PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT00683722
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Pulmonary Emphysema, Chronic Bronchitis
Interventions
Prochymal™, Placebo
Drug
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
Los Angeles, California • Torrance, California • Charlotte, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 31, 2026, 6:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

H5-VLP + GLA-AF Vaccine Trial in Healthy Adult Volunteers

NCT01657929
View directory record Official record
Conditions
Influenza A Subtype H5N1 Infection
Interventions
H5-VLP + GLA-AF, H5-VLP alone, H5-VLP + Alhydrogel(R), Licensed H5N1 vaccine
Biological
Lead sponsor
Access to Advanced Health Institute (AAHI)
Other
Eligibility
18 Years to 49 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
3
States / cities
Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 26, 2014 · Synced Oct 31, 2026, 6:40 AM EDT
Terminated Phase 2 Interventional Results available

Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection

NCT01199731
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK2248761 100 mg once daily, GSK2248761 200 mg once daily, Etravirine
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 31, 2026, 6:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, and Immunogenicity of Hantaan and Puumala Virus DNA Vaccines

NCT01502345
View directory record Official record
Conditions
Hemorrhagic Fever With Renal Syndrome
Interventions
Vaccine/device combination for prevention of HFRS
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 49 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 31, 2026, 6:40 AM EDT
Completed Not applicable Interventional

Procalcitonin Use in Pneumonia Patients in the Critical Care Setting

NCT01788488
View directory record Official record
Conditions
Pneumonia
Interventions
Use of procalcitonin as biomarker to guide therapy
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Eau Claire, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 25, 2013 · Synced Oct 31, 2026, 6:40 AM EDT
Completed Not applicable Interventional Results available

Technology-Based Intervention for Reducing Sexually Transmitted Infections and Substance Use During Pregnancy

NCT03826342
View directory record Official record
Conditions
Sexually Transmitted Infection, Alcohol Use Complicating the Puerperium, Alcohol Use Complicating Pregnancy, Unspecified Trimester, Drug Use
Interventions
Health Check-up for Expectant Moms, Time, attention, and information-matched control
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Oct 31, 2026, 6:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Microbial Colonization in Three Dimensional (3D) Printed Orthodontic Clear Aligners

NCT07143370
View directory record Official record
Conditions
Orthodontic Aligner, Microbial Colonization
Interventions
Thermoformed clear aligner, 3D printed clear aligner TC-85, 3D printed clear aligner TA-28
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 31, 2026, 6:40 AM EDT
Completed Not applicable Interventional

An Open-Label Study to Evaluate the Efficacy and Safety of Amprenavir (141W94) and Abacavir Combination Therapy in Protease Inhibitor Experienced Subjects With HIV-1 Infection Who Are Failing Their Current Antiretroviral Treatment Regimen

NCT00002205
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Amprenavir
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 31, 2026, 6:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Males to Measure Maraviroc in Blood, Saliva, Seminal Fluid, and Rectal Tissue

NCT00775294
View directory record Official record
Conditions
HIV/AIDS
Interventions
Maraviroc
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 49 Years · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 13, 2011 · Synced Oct 31, 2026, 6:40 AM EDT
Recruiting Phase 1 Interventional

TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.

NCT04013802
View directory record Official record
Conditions
Viral Infection
Interventions
HLA-matched VSTs
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 31, 2026, 6:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Ecological Momentary Assessment and Text Message Intervention for Stress Management

NCT04907942
View directory record Official record
Conditions
Stress, Psychological, Loneliness, Covid19, Stress
Interventions
EMA + EMA and FACE Stress, EMA Alone
Other
Lead sponsor
Click Therapeutics, Inc.
Industry
Eligibility
22 Years and older
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Oct 31, 2026, 6:40 AM EDT
Completed Phase 1 Interventional

Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc

NCT00703586
View directory record Official record
Conditions
HIV Infections
Interventions
Maraviroc
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 23, 2012 · Synced Oct 31, 2026, 6:40 AM EDT